Manufacturer record

Cipla Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

14 batches manufactured by Cipla Ltd (Goa) were declared Not of Standard Quality between May 2019 and May 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

14 records linked to Cipla Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
14Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, May 2019 to May 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

14
NSQ batches since 2019
13
Products affected
Assay
Most common failure
May 2026
Latest alert

Flagged batches per year

2019 · 12020 · 12021 · 22022 · 12023 · 32024 · 42025 · 12026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Paracetamol and Domperidone Tablets (Dompar) 4C11469Mfg 2024-12 · Exp 2027-11 DisintegrationDisintegration DTL KonniState lab May 2026
Tamsulosin Hydrochloride & Dutasteride tab (Urimax-D 4GH0097Mfg 2023-12 · Exp 2025-11 Negative for the presence of Tamsulosin Hydrochloride & DutasterideOther State Drug Control & Research Lab, West BengalState lab May 2025
METFORMIN HYDROCHLOR IDE TABLETS IP (OKAMET- 500) 4O30069Mfg 2024-02 · Exp 2027-01 Does not comply with respect to the Assay as per IP specificationAssay PuducherryState lab Dec 2024
Tofacitinib Tablets IP 5 mg (TOFAJAK TABLETS) 4F30009Mfg 2024-05 · Exp 2026-04 Identification and Assay of Tofacitinib citrate calculated as TofacitinibAssay RDTL ChandigarhCDSCO lab Nov 2024
Tamsulosin and Dutasteride Tablets (Urimax-D) GH30334Mfg 2023-05 · Exp 2025-04 Identification and Assay of Tamsulosin Hydrochloride , Dutasteride and Description.Assay CDL KolkataCDSCO lab Jul 2024
Budesonide Nebuliser Suspension BP (Budecort Respules) SN30395Mfg 2023-04 · Exp 2025-03 Assay of BudesonideAssay CDL KolkataCDSCO lab Jul 2024
Tamsulosin Hydrochloride & Dutasteride Tablets (Urimax D) GH20067Mfg 2022-01 · Exp 2024-12 Identification and Assay of Dutasteride and Assay of Tamsulosin HydrochlorideAssay CDL KolkataCDSCO lab Jul 2023
Urimax D (Tamsulosin Hydrochloride & Dutasteride Tablets) GH20067Mfg 2022-01 · Exp 2023-12 Identification & Assay of Tamsulosin Hydrochloride and Dutasteride The sample is deemed to be SpuriousAssay CDL KolkataCDSCO lab Apr 2023
Atorvastatin & Aspirin Capsules (10 / 75) AAC1010Mfg 2021-11 · Exp 2023-10 Dissolution of AtorvastatinDissolution CDL KolkataCDSCO lab Jan 2023
Junior Lanzol 15 mg (Lansoprazole Orally Disintegrating Tablets 15 mg) BA12571Mfg 2021-08 · Exp 2023-07 HardnessOther CDTL MumbaiCDSCO lab Dec 2022
Acivir - 800 DT (Aciclovir Dispersible Tablets IP 800 mg) SN01674Mfg 2020-10 · Exp 2023-09 Uniformity of DispersionUniformity of weight/content CDL KolkataCDSCO lab Oct 2021
Acivir-200 DT (Aciclovir Dispersible Tablets I.P. 200 mg) SA91192Mfg 2019-02 · Exp 2022-01 Uniformity of DispersionUniformity of weight/content CDL KolkataCDSCO lab Aug 2021
Asthalin - 4 (Salbutamol Sulphate Tablet I.P. 4 mg) SA81637Mfg 2018-04 · Exp 2021-03 Related SubstancesRelated substances CDL KolkataCDSCO lab Mar 2020
Nitrofurantoin Capsules USP 100mg (URIFAST CAPSULES) BA82286Mfg 2018-07 · Exp 2020-06 DissolutionDissolution RDTL ChandigarhCDSCO lab May 2019

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.